e-learning
resources
Milan 2017
Monday, 11.09.2017
Bronchodilators and bronchoprotectors
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Indacaterol/glycopyrronium (IND/GLY) reduces the risk of clinically important deterioration (CID) in patients with moderate COPD: Results from the CRYSTAL study
T. Greulich (Marburg, Germany)
Source:
International Congress 2017 – Bronchodilators and bronchoprotectors
Session:
Bronchodilators and bronchoprotectors
Session type:
Poster Discussion
Number:
1801
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
T. Greulich (Marburg, Germany). Indacaterol/glycopyrronium (IND/GLY) reduces the risk of clinically important deterioration (CID) in patients with moderate COPD: Results from the CRYSTAL study. 1801
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Umeclidinium/vilanterol in preventing clinically important deterioration (CID) in COPD and impact of baseline disease severity: the EMAX trial
Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies
Year: 2019
Mometasone/indacaterol/glycopyrronium (MF/IND/GLY) improves lung function and reduces exacerbations in patients with asthma, independent of baseline airflow limitation: Results from IRIDIUM study
Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence
Year: 2021
Indacaterol/glycopyrronium (IND/GLY) reduces the risk of clinically important deterioration (CID) versus open-label tiotropium (Tio) in COPD patients: Post hoc analysis from SHINE and SPARK studies
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016
Indacaterol/glycopyrronium (IND/GLY) reduces the risk of clinically important deterioration (CID) versus salmeterol/fluticasone (SFC): the FLAME study
Source: International Congress 2017 – Management of COPD
Year: 2017
Indacaterol/glycopyrronium (IND/GLY) delays clinically important deterioration (CID) versus salmeterol/fluticasone (SFC) in symptomatic COPD patients: LANTERN/ILLUMINATE pooled analysis
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016
Pulse wave velocity (PWV) in patients (pts) with moderate COPD and cardiovascular risk: The effect of an inhaled long-acting β2-agonist/corticosteroid (SUMMIT)
Source: International Congress 2016 – Novel insights into the treatment of COPD
Year: 2016
Cardiovascular (CV) safety of indacaterol/glycopyrronium (IND/GLY) compared with salmeterol/fluticasone combination (SFC) in moderate-to-very severe COPD patients with prior exacerbations: The FLAME study
Source: International Congress 2016 – Pharmacological management of COPD
Year: 2016
Management of high risk patients with COPD, identified by the DOSE index, in general practice
Source: Annual Congress 2009 - COPD case-finding and management in primary care
Year: 2009
Top-10 comorbidities of symptomatic patients with moderate COPD in the clinical setting of the CRYSTAL study
Source: International Congress 2016 – Features and impact of comorbidities in COPD
Year: 2016
Indacaterol/glycopyrronium (IND/GLY) improves lung function irrespective of gender baseline differences in patients with COPD: A pooled analysis from the IGNITE Program
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016
Prevalence of co-morbidities in Greek COPD patients in relation to the stage of the disease (COMPACT study)
Source: International Congress 2017 – Primary care pulmonary rehabilitation, multimorbidity and organisation of care
Year: 2017
Surfactant protein D (SPD) like marker of effectiveness in patients (pts) with acute exacerbations (AE) of COPD ofphosphatidylcholine treatment outcomes
Source: International Congress 2015 – Different data in COPD
Year: 2015
Lung function and treatment patterns of symptomatic patients with moderate COPD in the CRYSTAL study
Source: International Congress 2016 – Novel avenues in the treatment of COPD I
Year: 2016
Identifying a ‘frequent exacerbator‘ phenotype in a cohort of COPD patients (EXACO study)
Source: Annual Congress 2012 - Prevalences and characterstics of obstructive airway disease
Year: 2012
Estimating the number of patients’ needed to treat (NNT) with indacaterol/glycopyrronium to prevent COPD exacerbations: Results from the FLAME study
Source: International Congress 2017 – Primary care diagnosis, assessment and management of COPD
Year: 2017
Benefits of triple therapy in moderate, severe, and very severe COPD: subgroup analysis of the ETHOS trial
Source: Virtual Congress 2021 – Inhaled treatments for COPD: clinical trials and real-world studies
Year: 2021
LATE-BREAKING ABSTRACT: Indacaterol/glycopyrronium (IND/GLY) reduces the risk of exacerbations versus salmeterol/fluticasone (SFC) in moderate-to-very severe COPD patients irrespective of prior ICS/LABA/LAMA therapy: The FLAME study
Source: International Congress 2016 – Novel strategies on COPD and asthma management
Year: 2016
Two versus three months rehabilitation with the same number of sessions in patients with moderate to severe COPD: analysis of the results
Source: Eur Respir J 2004; 24: Suppl. 48, 244s
Year: 2004
Pilot: identification of rehospitalization risk factors for patients with COPD
Source: Annual Congress 2005 - Assessment and intervention from primary care centre to hospital
Year: 2005
Follow-up of patients with uncontrolled asthma: clinical features of asthma patients according to the level of control achieved (the COAS study)
Source: Eur Respir J , 49 (3) 1501885; DOI: 10.1183/13993003.01885-2015
Year: 2017
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept